| this review discusses how MYC suppresses immune surveillance, and how oncogene-targeted therapies may restore the immune response against tumors | None |
| Heart tumors specifically induced in young avian embryos by the v-myc oncogene. | None |
| The myc oncogene in avian and mammalian carcinogenesis. | None |
| Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. | None |
| within a limited region containing sequences with the potential to adopt multiple structures, only one structure predominates under a given condition. The predominance of H-DNA implicates this structure in the instability associated with the human c-MYC oncogene | None |
| Expression of c-myc proto-oncogene during the early development of Xenopus laevis. | None |
| Expression of the N-myc oncogene in Wilms tumour and related tissues. | None |
| [Viral myc oncogene in the genome of transgenic mice and their progeny]. | None |
| Different biological effects of c-myc and H-ras oncogene expression in EBV-infected human lymphoblasts. | None |
| Data, including data from studies in cells from knockout mice, suggest that Prmt1 activity was necessary for c-Myc binding to acetyltransferase p300 in myeloid cells; Prmt1 inhibition decreases p300 recruitment to c-Myc target promoters and increased Hdac1 recruitment. [Prmt1, protein arginine N-methyltransferase 1; c-Myc = Proto-Oncogene Proteins c-myc; Hdac1 = histone deacetylase 1] | None |
| Here the authors show that sublethal activation of Caspase-3 plays an essential, facilitative role in Myc-induced genomic instability and oncogenic transformation. | None |
| Luciferase reporter assay showed that c-Myc, an oncogene that regulating cell survival, angiogenesis and metastasis, was a direct target of miR-376a. Over-expression of miR-376a decreased the mRNA and protein levels of c-Myc in A549 cells. | None |
| deficiency alters the expression of a crucial subset of TAL1- and NOTCH1-regulated genes, including the MYB and MYC oncogenes, respectively. | None |
| 1,25-Dihydroxyvitamin D3, the c-myc oncogene, and cell regulation. | None |
| Characterization of lymphoid tumors induced by a recombinant murine retrovirus carrying the avian v-myc oncogene. Identification of novel (B-lymphoid) tumors in the thymus. | None |
| Sustained exposure of cells to TGF-beta resulted in recovery from proliferative arrest in association with amplification of the Myc proto-oncogene, with MYC inhibiting TRIM26 induction by TGF-beta. | None |
| In our study, the c-myc oncogene was amplified in 11.1% of BPH samples. Bivariate analysis failed to reveal any significant association between oncogene amplification and the clinicopathologic variables examined. | None |
| MYC-driven tumor initiation relies on cell reprogramming, which is mediated by the activation of MYC-dependent oncogenic enhancers. | None |
| Study identifies Eya3 as a regulator of PP2A, a major cellular Ser/Thr phosphatase, and uncovers a mechanism of controlling the stability of a critical oncogene, c-Myc. | None |
| Colocalization of the myc oncogene protein and small nuclear ribonucleoprotein particles. | None |